JP2012530113A - より良好な生物学的利用能を示すホスホネート誘導体の合成のためのホスホネートシントン - Google Patents
より良好な生物学的利用能を示すホスホネート誘導体の合成のためのホスホネートシントン Download PDFInfo
- Publication number
- JP2012530113A JP2012530113A JP2012515500A JP2012515500A JP2012530113A JP 2012530113 A JP2012530113 A JP 2012530113A JP 2012515500 A JP2012515500 A JP 2012515500A JP 2012515500 A JP2012515500 A JP 2012515500A JP 2012530113 A JP2012530113 A JP 2012530113A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- branched
- compound
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 22
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 22
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title claims description 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 title abstract description 26
- 229940002612 prodrug Drugs 0.000 claims abstract description 18
- 239000000651 prodrug Substances 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 49
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 35
- -1 hexadecyloxypropyl Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 150000001336 alkenes Chemical group 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 7
- 125000003700 epoxy group Chemical group 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 4
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 238000005686 cross metathesis reaction Methods 0.000 abstract description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 153
- 229910052760 oxygen Inorganic materials 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 20
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 11
- 229960002949 fluorouracil Drugs 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 229940113082 thymine Drugs 0.000 description 10
- 229940035893 uracil Drugs 0.000 description 10
- 239000003039 volatile agent Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- NZRFSLMXTFGVGZ-UHFFFAOYSA-N n-[diethylamino(prop-2-enoxy)phosphoryl]-n-ethylethanamine Chemical compound CCN(CC)P(=O)(N(CC)CC)OCC=C NZRFSLMXTFGVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical class ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical compound OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- CQCXMYUCNSJSKG-UHFFFAOYSA-N 1-dimethoxyphosphorylethene Chemical compound COP(=O)(OC)C=C CQCXMYUCNSJSKG-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ZOSQAGGCVFVCNO-UHFFFAOYSA-N 3-dimethoxyphosphorylprop-1-ene Chemical compound COP(=O)(OC)CC=C ZOSQAGGCVFVCNO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 description 2
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- JHYNXXBAHWPABC-UHFFFAOYSA-N chloromethyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OCCl JHYNXXBAHWPABC-UHFFFAOYSA-N 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- UUMSDSAHAYSSSQ-UHFFFAOYSA-N phenylmethoxymethylphosphonic acid Chemical compound OP(O)(=O)COCC1=CC=CC=C1 UUMSDSAHAYSSSQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-M 2,2-dimethylbutanoate Chemical compound CCC(C)(C)C([O-])=O VUAXHMVRKOTJKP-UHFFFAOYSA-M 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- PKXYFOQKRMBDCQ-UHFFFAOYSA-N 2-phenylpropan-2-yl dihydrogen phosphate Chemical compound OP(=O)(O)OC(C)(C)C1=CC=CC=C1 PKXYFOQKRMBDCQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108010076278 Adenosine kinase Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MIALNUQJPKBDPR-RELWKKBWSA-N C(CCCCCCCCCCCCCCC)C(/C=C/CN1C(=O)NC(=O)C=C1)([PH2]=O)CCC Chemical compound C(CCCCCCCCCCCCCCC)C(/C=C/CN1C(=O)NC(=O)C=C1)([PH2]=O)CCC MIALNUQJPKBDPR-RELWKKBWSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- BPYBCKBGKAIOBH-UHFFFAOYSA-N [methyl(phenylmethoxy)phosphoryl]oxymethylbenzene Chemical compound C=1C=CC=CC=1COP(=O)(C)OCC1=CC=CC=C1 BPYBCKBGKAIOBH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001344 alkene derivatives Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical compound CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003695 memory enhancer Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZVXQITNIMKKBBE-UHFFFAOYSA-N n-cyclopropyl-7h-purin-6-amine Chemical class C1CC1NC1=NC=NC2=C1N=CN2 ZVXQITNIMKKBBE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 1
- BJLZAAWLLPMZQR-UHFFFAOYSA-N oxo-di(propan-2-yloxy)phosphanium Chemical compound CC(C)O[P+](=O)OC(C)C BJLZAAWLLPMZQR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- KOQWNNWKXQMCOU-UHFFFAOYSA-N propan-2-yloxymethyl hydrogen carbonate Chemical compound CC(C)OCOC(O)=O KOQWNNWKXQMCOU-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【選択図】なし
Description
Rは、
* 式(1)
p は、
n は0〜5の整数であり、
X およびY は互いに独立して、水素、ハロゲン、直鎖もしくは分枝の(C1-C6)アルキル基またはヒドロキシメチル基を表し、
* -式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1C6)アルコキシ基である)
のオキシメチルカルボニル基、但し、Rがシス-プロペニル
R3 は直鎖もしくは分枝の(C1-C6)アルキル基である)
のチオエチルカルボニル基、
を含む基から選択される基を表すか、または
のシクロアルキレン基を形成する]
の化合物である、但し、
である、式(I)の化合物に相当する。
本発明のもう一つの目的は、薬物Dを本発明の式(I)の化合物と接触させる工程を含む親油性プロ-薬物を製造する方法である。
D はオレフィン基を有する薬物であり、
A は1以上の2重結合を含む(C1-C6)アルケニル基であり、
R'およびR"は互いに独立して、
* -式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1-C6)アルコキシ基である)
のオキシメチルカルボニル基、
のチオエチルカルボニル基、
-親油性鎖
を表すか、または
のシクロアルキレン基を形成する]
の化合物を製造する方法であり、それは、
の化合物を提供し、
の化合物と反応させ、式(II-1)の化合物を得、
c) 式(II-1)の化合物を単離する
の工程を含む。
m = 0 または1であり、
D は薬物であり、
* - 式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は、直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1-C6)アルコキシ基である)
のオキシメチルカルボニル基、
のチオエチルカルボニル基、
- 親油性鎖
を含む基から選択される基を表すか、または
* R'およびR"は、それらが結合するホスホネート原子と一緒に、式(4)
のシクロアルキレン基を形成する]
の化合物を製造する方法であり、それは、
の化合物と反応させ、式(II-2)の化合物を得、
f) 式(II-2)の化合物を単離する
の工程を含む。
直鎖もしくは分枝の(C1-C6)アルキル基の用語は、メチル、エチル、プロピル、イソプロピル、n-ブチル、イソブチル、t-ブチル、n-ヘキシルのような1〜6個のC-原子を含む直鎖もしくは分枝の炭化水素残基を意味する。
直鎖もしくは分枝の(C2-C6)アルケニル基の用語は、1以上のオレフィン結合と 6個まで、好ましくは4個までのC-原子を含む、直鎖もしくは分枝の炭化水素残基 を意味する。オレフィン(olefin)およびオレフィン(olefine)は、アルケニル基を 意図するためにも用いられ得る。
脱離基の用語は、分子からそれ自身を分離する能力を有するイオン(金属)または置換基、例えばハロゲン、スルホニル基、例えばp-トルエンスルホニル等である。
D は、生物活性を有する化合物、例えば、限定されないが、神経伝達物質、興奮剤、ドーパミン作動薬、トランキライザー、抗うつ剤、麻薬性鎮痛薬、麻薬拮抗薬、鎮静剤、睡眠薬、麻酔薬、抗てんかん薬/鎮痙薬、男性および女性ホルモンのようなホルモン、ペプチド、抗炎症ステロイド、非ステロイド抗炎症薬/非麻薬性鎮痛薬、記憶増強剤、抗菌剤/抗生物質、抗新生物薬(抗癌剤/抗腫瘍剤)および抗ウイルス剤から選択される。
本発明のもう一つの目的は、薬物として使用のための式
したがって、本発明のシントンを用いて、フリーのヌクレオシドへのアリル ビス-POM/POC アリルホスホネートの直接的な交差メタセシス(direct Cross Metathesis)により、ビス-POM/POC アシルヌクレオシド ホスホネート プロドラッグを合成することができる。それらは、同じ工程で、リンとPOM/POCプロドラッグ部分を導入することを可能にする。
実施例1〜15は、本発明のシントンの合成を説明する。
実施例16〜48は、前記シントンからのプロドラッグの合成を説明する。
1.1. ジアルキル アルキルホスホネートに親油性鎖の導入
ジアルキル アルキルホスホネート (1 当量)のジクロロメタン (DCM) (5mL/mmol)の溶液に、オキサリル クロライド (3 当量)を加え、乾燥アルゴンの陽圧下、穏やかに24時間還流した。この溶液を減圧下に蒸発し、DCM (5mL/mmol)で希釈した。次いで、親油性アルコール (1.05 当量)および乾燥トリエチルアミン (1.5 当量)を加え、該溶液を乾燥アルゴンの陽圧下、48時間還流した。揮発性物質を蒸発し、残渣をシリカゲルのクロマトグラフィーで精製し、対応するアルキル/親油性鎖 アルキルホスホネートを得た。
ジメチル アルキルホスホネート (1 当量)および無水ヨウ化ナトリウム (2 当量)のアセトニトリル ACN (1 mL/mmol)溶液に、クロロメチル ピバレート POMCl (2.5 当量)またはクロロメチル イソプロピル カーボネート (2.5 当量)を加えた。この溶液を、乾燥アルゴンの陽圧下、48時間還流下に撹拌した。冷却後、ジエチルエーテルを加え(10 mL/mmol)、溶液を水で洗浄(2mL/mmol)した。有機層を硫酸マグネシウムで乾燥し、蒸発させ、シリカゲルのクロマトグラフィーで精製し、対応するビス-(POM)またはビス-(POC) アルキルホスホネートを得た。
メチル/プロドラッグ基 アルキルホスホネート (1 当量)および無水ヨウ化ナトリウム (1 当量)のACN (1 mL/mmol)溶液に、クロロメチル ピバレート POMCl (1.5 当量)またはクロロメチル イソプロピル カーボネート (1.5 当量)を加えた。この溶液を、乾燥アルゴンの陽圧下、48時間還流下に撹拌した。冷却後、ジエチルエーテル (10 mL/mmol)を加え、溶液を水 (2mL/mmol)で洗浄した。有機層を硫酸マグネシウムで乾燥し、蒸発させ、シリカゲルのクロマトグラフィーで精製し、対応するビス-(POM)またはビス-(POC) アルキルホスホネートを得た。
アルゴン下、1,3-ビス(シクロヘキシル)イミダゾリウム テトラフルオロボレート (IcyHBF4) 塩 (0.05 当量)のテトラヒドロフラン (THF) (1 mL/mmol)の溶液およびモレキュラーシーブ (0.5g/mmol)に、tBuOK (0.9 当量)を加え、10分間撹拌する。親油性アルコール (1 当量)およびジアルキル H-ホスフネート (2 当量)を加え、反応混合物を室温で24時間撹拌した。反応混合物を塩化アンモニウムの飽和溶液 (5 mL/mmol)でクエンチし(quenched)、セライトで濾過する。該溶液に酢酸エチル (AcOEt) (10 mL/mmol)を加え、次いで、有機層と水層を分離する。次いで、水層をAcOEt (10 mL/mmol)で抽出し、合わせた有機層を真空下に蒸発させる。最後に、対応するアルキル/親油性鎖 H-ホスホネートをシリカゲルのクロマトグラフィーで精製する。
31P NMR (162 MHz, CDCl3): δ = 10.05
13C NMR (100 MHz, CDCl3) δ = 176.5 (C=O), 81.1, 81.0 (O-CH2-O), 38.4 (C(CH3)3), 26.6 (C(CH3)3), 12.9, 11.5 (CH3-P)
31P NMR (162 MHz, CDCl3): δ = 31.54
31P NMR (162 MHz, CDCl3): δ = 31.23
13C NMR (100 MHz, CDCl3): δ = 153.1 (C=O), 136.9, 136.8 (CH2=CH), 125.6, 123.7 (CH2=CH), 84.1, 84.0 (O-CH2-O), 73.2 (CH(CH3)2), 21.6 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 16.89
13C NMR (100 MHz, CDCl3) δ = 176.7 (C=O), 136.6 (2C, CH2=CH), 126.0, 124.1 (CH2=CH), 81. 5, 81.4 (O-CH2-O), 38.7, 38.4 (C(CH3)3), 27.0, 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 17.14
31P NMR (162 MHz, CDCl3): δ = 18.80
13C NMR (100 MHz, CDCl3) δ = 176.6 (C=O), 125.8, 125.7 (CH2=CH), 121.0, 120.9 (CH2=CH), 81.4, 81.3 (O-CH2-O), 38.6 (C(CH3)3), 32.7, 31.3 (CH2-P), 26.7 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 27.71
13C NMR (100 MHz, CDCl3) δ = 153.2 (C=O), 125.7, 125.6 (CH2=CH), 121.3, 121.2 (CH2=CH), 84.1, 84.0 (O-CH2-O), 73.2 (CH(CH3)2), 32.9, 31.5 (CH2-P), 21.6 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 27.99
31P NMR (162 MHz, CDCl3) δ = 28.3
31P NMR (162 MHz, CDCl3) δ = 26.7
13C NMR (100 MHz, CDCl3) δ =・176.7 (C=O), 136. 5, 128.4, 128.1, 128.0 (CAr), 81.6 (2C, O-CH2-O), 75.0, 74.9 (Ph-CH2), 64.7, 63.0 (O-CH2-P), 38.6 (C(CH3)3), 26.7 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 21.79
化合物12は次のスキーム12にしたがって合成される。
13C NMR (100 MHz, CDCl3) δ ppm 177.0 (C=O), 81.8, 81.7 (O-CH2-O), 58.2, 56.6 (O-CH2-P), 38.7 (C(CH3)3), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 24.07
13C NMR (100 MHz, CDCl3) ( ppm = 176.9 (C=O), 135.9, 135.7 (CH=CH), 119.0, 118.9 (CH=CH), 81.6, 81.5 (O-CH2-O), 62.9 (2C, HOCH2), 38.7 (C(CH3)3), 31.4, 30.1 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 27.54
13C NMR (100 MHz, CDCl3) δ ppm = 176.9 (C=O), 135.9, 135.7 (CH=CH), 119.0, 118.9 (CH=CH), 81.6, 81.5 (O-CH2-O), 62.9 (2C, HOCH2), 38.7 (C(CH3)3), 31.4, 30.1 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.77
13C NMR (100 MHz, CDCl3) δ = 176.9 (C=O), 118.4 (q, J = 318 Hz, CF3), 82.2 (2C, O-CH2-O), 67.0, 65.3 (CH2-P), 38.7 (C(CH3)3), 26.7 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 12.17
N1-クロチル-5-置換ウラシル (1 当量)および実施例 8で製造されたビス-(POM)アリルホスホネート (1.3 当量)のCH2Cl2 (25 mL/mmol)の溶液に、IMes 触媒 (0.05 当量)を加えた。この溶液を、乾燥アルゴンの陽圧下、示された時間穏やかに還流した。全ての揮発性物質を蒸発後、残渣をシリカゲルのクロマトグラフィー(EtOAc/EP)で精製した。
本手順は、次のスキームに示される。
1H NMR (400 MHz, CDCl3) δ = 8.73 (s, 1H, NH), 7.17 (d, J = 7.9 Hz, 1H, H6), 5.75-5.61 (m, 7H, O-CH 2 -O, CH=CH, H5), 4.32 (t, J = 4.1 Hz, 2H, U-CH 2 ), 2.72 (dd, J = 22.4 Hz, 5.0 Hz, 2H, P-CH 2 ), 1.23 (s, 18H, tBu)
13C NMR (100 MHz, CDCl3) δ = 176.8 (C=O), 163.2 (C=O), 150.5 (C=O), 143.4 (C6), 129.5, 129.3 (CH=CH), 124.1, 124.0 (CH=CH), 102.6 (C 5), 81.6, 81.5 (O-CH2-O), 49.1, 49.0 (U-CH2), 38.7 (C(CH3)3), 31.5, 30.1 (P-CH2), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 26.4
IR ν cm-1: 2977 ; 1751 ; 1685 ; 1459 ; 1242 ; 1138 ; 956 ; 855
1H NMR (400 MHz, CDCl3) δ = 8.32 (s, 1H, NH), 7.47 (d, J = 7.9 Hz, 1H, H6), 5.77-5.60 (m, 7H, O-CH 2 -O, CH=CH, H5), 4.44 (t, J = 4.7 Hz, 2H, U-CH 2 ), 2.82 (dd, J = 23.4, 6.7 Hz, 2H, P-CH 2 ), 1.24 (s, 18H, tBu)
13C NMR (100 MHz, CDCl3) δ = 177.0 (C=O), 163.2 (C=O), 150.6 (C=O), 144.4 (C6), 129.1, 128.9 (CH=CH), 122.1, 122.0 (CH=CH), 102.5 (C 5), 81.6, 81.5 (O-CH2-O), 44.8, 44.7 (U-CH2), 38.8 (C(CH3)3), 27.0および25.6 (P-CH2), 26.9 (C(CH3)3)
31P NMR (162 MHz, CDCl3) δ = 26.6
1H NMR (400 MHz, CDCl3): δ = 9.58 (s, 1H, NH), 7.28 (d, J = 5.5 Hz, 1H, H6), 5.77-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.31 (t, J = 4.9 Hz, 2H, U-CH 2 ), 2.72 (dd, J = 22.6 Hz, 5.3 Hz, 2H, P-CH 2 ), 1.22 (s, 18H, tBu)
13C NMR (100 MHz, CDCl3): δ = 176.8 (C=O), 157.2, 156.9 (C=O), 149.3 (C=O), 141.7, 139.3 (C 5), 129.1, 128.9 (CH=CH), 127.7, 127.4 (C 6), 124.7, 124.6 (CH=CH), 81.6, 81.5 (O-CH2-O), 49.3 (2C, U-CH2), 38.6 (C(CH3)3), 31.4, 30.0 (P-CH2), 26.7 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.3.
IR ν cm-1: 2977 ; 2361 ; 1752 ; 1702 ; 1480 ; 1238 ; 1137 ; 965 ; 871
1H NMR (400 MHz, CDCl3): δ = 8.59 (s, 1H, NH), 7.73 (d, J = 5.8 Hz, 1H, H6), 5.75-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.44 (t, J = 4.7 Hz, 2H), 2.80 (dd, J = 6.8 Hz, 23.5 Hz, 2H, P-CH 2 ), 1.23 (s, 18H, tBu)
13C NMR (100 MHz, CDCl3): δ = 177.0 (C=O), 157.0, 156.7 (C=O), 149.2 (C=O), 141.7, 139.4 (C 5), 128.9, 128.7, 128.6 (2C, CH=CH, およびC6), 122.6, 122.5 (CH=CH), 81.7, 81.6 (O-CH2-O), 44.9 (2C, U-CH2), 38.8 (C(CH3)3), 26.9および25.5 (P-CH2), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.4
1H NMR (400 MHz, CD3OD): δ = 7.37 (d, J = 0.9 Hz, 1H, H6), 5.85-5.74 (ttd, J = 5.1 Hz, 11.2 Hz, 15.4 Hz, 1H, CH=CH), 5.66 (m, 5H, O-CH 2 -O, CH=CH), 4.32 (t, J = 5.2 Hz, 2H, T-CH 2 ), 2.82 (dd, J = 22.5 Hz, 7.2 Hz, 2H, P-CH 2 ), 1.87 (s, 3H, CH 3 -U) 1.23 (s, 18H, tBu)
13C NMR (100 MHz, CD3OD): δ = 178.1 (C=O), 166.8 (C=O), 152.7 (C=O), 142.4 (C6), 131.8, 131.6 (CH=CH), 123.7, 123.6 (CH=CH), 111.5 (C 5), 83.2, 83.1 (O-CH2-O), 49.9 (2C, U-CH2), 39.7 (C(CH3)3), 31.8, 30.4 (P-CH2), 27.2 (C(CH3)3), 12.3 (CH3-U)
31P NMR (162 MHz, CD3OD): δ = 27.3
IR ν cm-1: 2929 ; 1678 ; 1453, 1396 ; 1196 ; 986 ; 751
1H NMR (400 MHz, CD3OD): δ ppm 7.46 (d, J = 1.2 Hz, 1H, H6), 5.78-5.60 (m, 7H, O-CH 2 -O, CH=CH), 4.40 (dd, J = 3.8 Hz, 5.5 Hz, 2H), 3.01 (dd, J = 23.2, 7.8 Hz, 2H, P-CH 2 ), 1.88 (d, J = 1.11 Hz, 3H, CH 3 -U), 1.24 (d, J = 3.16 Hz, 18H, tBu)
13C NMR (100 MHz, CD3OD): δ = 178.2 (C=O), 166.9 (C=O), 152.9 (C=O), 142.7 (C6), 130.6, 130.4 (CH=CH), 123.0, 122.8 (CH=CH), 111.5 (C 5), 83.2, 83.1 (O-CH2-O), 45.6 (U-CH2), 39.8 (C(CH3)3), 27.7および26.3 (P-CH2), 27.3 (C(CH3)3), 12.3 (CH3-U)
31P NMR (162 MHz, CD3OD): δ = 27.6
1H NMR (400 MHz, CDCl3): δ = 8.73 (s, 1H, NH), 7.42 (s, 1H, H6), 5.80-5.60 (m, 6H, O-CH 2 -O, CH=CH), 4.33 (t, J = 4.5 Hz, 2H, U-CH 2 ), 2.72 (dd, J = 5.7 Hz, 22.6 Hz, 2H, P-CH 2 ), 1.23 (s, 18H, tBu)
13C NMR (100 MHz, CDCl3): δ = 176.8 (C=O), 158.8 (C=O), 149.4 (C=O), 140.3 (C6), 129.0, 128.8 (CH=CH), 125.0, 124.9 (CH=CH), 109.0 (C 5), 81.6 (2C, O-CH2-O), 49.5 (2C, U-CH2), 38.7 (C(CH3)3), 31.5, 30.1 (P-CH2), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.1
IR ν cm-1: 2976 ; 1752 ; 1692 ; 1452 ; 1236 ; 1135 ; 963 ; 853
1H NMR (400 MHz, CDCl3): δ = 8.48 (s, 1H, NH), 7.79 (s, 1H, H6), 5.74-5.62 (m, 6H, O-CH 2 -O, CH=CH), 4.47 (t, J = 4.63 Hz, 2H, U-CH 2 ), 2.82 (dd, J = 23.5 Hz, 6.9 Hz, 2H, P-CH 2 ), 1.24 (s, 18H)
13C NMR (100 MHz, CDCl3): δ = 177.0 (C=O), 158.9 (C=O), 149.7 (C=O), 141.3 (C6), 128.6, 128.4 (CH=CH), 122.7, 122.6 (C 6), 108.9 (C 5), 81.7, 81.6 (O-CH2-O), 45.1 (2C, U-CH2), 38.8 (C(CH3)3), 27.0および25.6 (P-CH2), 26.8 (C(CH3)3)
1H NMR (400 MHz, CD3OD): δ = 7.98 (s, 1H, H6), 5.85-5.76 (m, 1H, CH=CH), 5.75-5.62 (m, 5H, O-CH 2 -O, CH=CH), 4.36 (t, J = 5.1 Hz, 2H, U-CH 2 ), 2.82 (dd, J = 22.5 Hz, 6.9 Hz, 2H, P-CH 2 ), 1.23 (s, 18H, tBu)
13C NMR (100 MHz, CD3OD): δ = 178.1 (C=O), 162.1 (C=O), 152.0 (C=O), 146.2 (C6), 131.4, 131.3 (CH=CH), 124.5, 124.4 (CH=CH), 96.8 (C 5), 83.3, 83.2 (O-CH2-O), 50.6, 50.5 (U-CH2), 39.8 (C(CH3)3), 31.9, 30.5 (P-CH2), 27.2 (C(CH3)3)
31P NMR (162 MHz, CD3OD): δ = 27.1
IR ν cm-1: 2976 ; 2361 ; 1751 ; 1693 ; 1441 ; 1235 ; 1137 ; 965 ; 854, 768
1H NMR (400 MHz, CD3OD): δ = 8.06 (s, 1H, H6), 5.70-5.52 (m, 6H, O-CH 2 -O, CH=CH), 4.45 (dd, J = 6.8 Hz, 3.7 Hz, 2H), 3.01 (dd, J = 23.4, 7.8 Hz, 2H), 1.24 (s, 18H)
13C NMR (100 MHz, CD3OD): δ = 178.2 (C=O), 162.2 (C=O), 152.1 (C=O), 146.3 (C6), 130.1, 129.9 (CH=CH), 123.5, 123.4 (CH=CH), 96.7 (C 5), 83.2, 83.1 (O-CH2-O), 46.2 (2C, U-CH2), 39.8 (C(CH3)3), 27.7および26.3 (P-CH2), 27.3 (C(CH3)3)
31P NMR (100 MHz, CD3OD): δ = 27.5
N1-クロチル-5-置換ウラシル (1 当量)および実施例 9により製造されたビス-(POC) アリルホスホネート (1.3 当量)のCH2Cl2 (25 mL/mmol)溶液に、IPr 触媒 (0.05 当量)を加えた。この溶液を、乾燥アルゴン陽圧下、示された時間、室温で撹拌した。全ての揮発性物質を蒸発後、残渣をシリカゲルのクロマトグラフィー(EtOAc/EP)で精製した。
本手順は、次のスキームに示される。
1H NMR (400 MHz, CDCl3) δ = 8.94 (s, 1H, NH), 7.19 (d, J = 7.9 Hz, 1H, H6), 5.74-5.61 (m, 7H, O-CH 2 -O, CH=CH, H5), 4.92 ( sept., J = 6.2 Hz, 2H, CH(CH3)2), 4.33 (t, J = 4.4 Hz, 2H, U-CH2), 2.76 (dd, J = 22.8, 5.6 Hz, 2H, P-CH 2 ), 1.32 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3) δ = 163.3 (C=O), 153.0 (C=O), 150.6 (C=O), 143.4 (C6), 129.7, 129.6 (CH=CH), 123.8, 123.7 (CH=CH), 102.5 (C5), 84.1, 84.0 (O-CH2-O), 73.4 (CH(CH3)2), 48.9 (2C, U-CH2), 31.3, 29.9 (P-CH2), 21.6 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.8
IR ν cm-1: 2896 ; 1755 ; 1679 ; 1457 ; 1257 ; 1152 ; 1100 ; 981 ; 949 ; 830
1H NMR (400 MHz, CDCl3): δ = 8.36 (s, 1H, NH), 7.30 (d, J = 5.6 Hz, 1H, H6), 5.80-5.60 (m, 7H, O-CH 2 -O, CH=CH, H5), 4.93 (sept, J = 6.3 Hz, 2H, CH(CH3)2), 4.32 (t, J = 4.17 Hz, 2H, U-CH2), 2.77 (dd, J = 22.9, 5.5 Hz, 2H, P-CH 2 ), 1.33 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 163.5 (C=O), 153.1 (C=O), 148.8 (C=O), 141.7 (C6), 129.2, 129.1 (CH=CH), 127.8, 127.5 (CH=CH), 124.6, 124.5 (CH=CH), 84.2, 84.1 (O-CH2-O), 73. (CH(CH3)2), 49.3 (2C, U-CH2), 31.3, 29.9 (P-CH2), 21.6 (2C, CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.6
1H NMR (400 MHz, CDCl3): δ = 9.06 (s, 1H, NH), 7.00 (d, J = 1.0 Hz, 1H, H6), 5.76-5.60 (m, 6H, O-CH 2 -O, CH=CH), 4.91 ( sept., J = 6.3 Hz, 2H, CH(CH3)2), 4.30 (t, J = 4.6 Hz, 2H, U-CH2), 2.74 (dd, J = 22.6 Hz, 5.9 Hz, 2H, P-CH 2 ), 1.90 (d, J = 0.7 Hz, 3H, CH3-U), 1.31 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 164.0 (C=O), 153.0 (C=O), 150.7 (C=O), 139.4 (C6), 130.1, 130.0 (CH=CH), 123.3, 123.1 (CH=CH), 111.0 (C 5), 84.1, 84.0 (O-CH2-O), 73.3 (CH(CH3)2), 48.7 (2C, U-CH2), 31.3, 29.9 (P-CH2), 21.5 (2C, CH(CH3)2), 12.2 (CH3-U)
31P NMR (162 MHz, CDCl3): δ = 27.0
IR ν cm-1: 2985 ; 1756 ; 1679 ; 1467 ; 1257 ; 1152 ; 1101 ; 982 ; 950 ; 831 ; 788
1H NMR (400 MHz, CDCl3): δ = 8.13 (s, 1H, NH), 7.23 (d, J = 1.2 Hz, 1H, H6), 5.76-5.61 (m, 6H, O-CH 2 -O, CH=CH), 5.00-4.87 (sept, J = 6.3 Hz, 2H, CH(CH3)2), 4.41 (t, J = 4.6 Hz, 2H, U-CH2), 2.88 (dd, J = 23.2, 6.3 Hz, 2H, P-CH 2 ), 1.92 (s, 3H, CH3-U), 1.33 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 163.7 (C=O), 153.1 (C=O), 150.6 (C=O), 140.1 (C6), 129.4, 129.3 (CH=CH), 121.6, 121.5 (CH=CH), 110.9 (C 5), 84.1 (2C, O-CH2-O), 73.4 (CH(CH3)2), 44.4 (2C, U-CH2), 27.0, 25.6 (P-CH2), 21.6 (CH(CH3)2), 12.2 (CH3-U)
31P NMR (162 MHz, CDCl3) δ = 26.8
1H NMR (400 MHz, CDCl3): δ = 9.44 (s, 1H, NH), 7.31 (d, J = 5.5 Hz, 1H, H6), 5.78-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.92 (sept, J = 6.3 Hz, 2H, CH(CH3)2), 4.32 (t, J = 4.6 Hz, 2H, U-CH2), 2.77 (dd, J = 23.0, 5.1 Hz, 2H, P-CH 2 ), 1.31 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 157.2, 156.9 (C=O), 153.1 (C=O), 149.3 (C=O), 141.8, 139.4 (C5), 129.4, 129.2 (CH=CH), 127.8, 127.5 (C 6), 124.4, 124.3 (CH=CH), 84.2 (2C, O-CH2-O), 73.5 (CH(CH3)2), 49.3, 49.2 (U-CH2), 31.3, 29.9 (P-CH2), 21.6 (2C, CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.8
IR ν cm-1: 2987 ; 1756 ; 1694 ; 1468 ; 1259 ; 1152 ; 1101 ; 981 ; 949 ; 870 ; 831 ; 787
1H NMR (400 MHz, CDCl3): δ = 8.40 (s, 1H, NH), 7.70 (d, J = 5.8 Hz, 1H, H6), 5.78-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.94 (sept, J = 6.3 Hz, 2H, CH(CH3)2), 4.45 (t, J = 4.8 Hz, 2H, U-CH2), 2.93-2.79 (dd, J = 23.7, 6.8 Hz, 2H, P-CH 2 ), 1.33 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 157.2, 156.9 (C=O), 153.178 (C=O), 149.2 (C=O), 128.9, 128.7 (CH=CH), 122.4, 122.2 (CH=CH), 84.3 (2C, O-CH2-O), 73.5 (CH(CH3)2), 44.9 (2C, U-CH2), 26.9, 25.5 (P-CH2), 21.6 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.6
1H NMR (400 MHz, CDCl3): δ = 9.31 (s, 1H, NH), 7.45 (s, 1H, H6), 5.76-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.92 ( sept., J = 6.3 Hz, 2H, CH(CH3)2), 4.34 (t, J = 4.2 Hz, 2H, U-CH2), 2.77 (dd, J = 22.8, 5.6 Hz, 2H, P-CH 2 ), 1.31 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 159.1 (C=O), 153.0 (C=O), 149.7 (C=O), 140.4 (C6), 129.3, 129.2 (CH=CH), 124.5, 124.4 (CH=CH), 109.0 (C 5), 84.2, 84.1 (O-CH2-O), 73.4 (CH(CH3)2), 49.4 (2C, U-CH2), 31.3, 29.9 (P-CH2), 21.6, 21.5 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.7
IR ν cm-1: 2986 ; 1756 ; 1686 ; 1451 ; 1348 ; 1258 ; 1152 ; 1186 ; 981 ; 949 ; 903 ; 869 ; 831 ; 787
1H NMR (400 MHz, CDCl3): δ = 8.79 (s, 1H, NH), 7.76 (s, 1H, H6), 5.74-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.93 ( sept., J = 6.3 Hz, 2H, CH(CH3)2), 4.47 (t, J = 4.7 Hz, 2H, , U-CH2), 2.87 (dd, J = 23.6, 6.7 Hz, 2H, P-CH 2 ), 1.32 (d, J = 6.3 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 159.0 (C=O), 153.1 (C=O), 149.7 (C=O), 141.3 (C6), 128.7, 128.6 (CH=CH), 122.4, 122.3 (CH=CH), 108.9 (C 5), 84.2, 84.1 (O-CH2-O), 73.5 (CH(CH3)2), 45.1, 45.0 (U-CH2), 26.9, 25.5 (P-CH2), 21.6 (CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.6
1H NMR (400 MHz, CDCl3): δ = 9.45 (s, 1H, NH), 7.51 (s, 1H, H6), 5.75-5.55 (m, 6H, O-CH 2 -O, CH=CH), 4.87 (sept., J = 6.3 Hz, 2H, CH(CH3)2), 4.29 (t, J = 4.1 Hz, 2H, U-CH2), 2.72 (dd, J = 22.4, 5.2 Hz, 2H, P-CH 2 ), 1.26 (d, J = 6.27 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 159.3 (C=O), 153.1 (C=O), 150.0 (C=O), 143.0 (C6), 129.4, 129.3 (CH=CH), 124.5, 124.4 (CH=CH), 96.7 (C 5), 84.2 (2C, O-CH2-O), 73.4 (CH(CH3)2), 49.4 (2C, U-CH2), 31.3, 29.9 (P-CH2), 21.6 (2C, CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.8
IR ν cm-1: 2986 ; 1756 ; 1691 ; 1442 ; 1347 ; 1260 ; 1153 ; 1186 ; 1029 ; 983 ; 951 ; 871 ; 832 ; 789
1H NMR (400 MHz, CDCl3): δ = 8.40 (s, 1H, NH), 7.86 (s, 1H, H6), 5.76-5.61 (m, 6H, O-CH 2 -O, CH=CH), 4.94 (sept, J = 6.3 Hz, 2H, CH(CH3)2), 4.47 (t, J = 4.6 Hz, 2H, U-CH2 ), 2.87 (dd, J = 23.6, 6.8 Hz, 2H, P-CH 2 ), 1.33 (d, J = 6.2 Hz, 12H, CH(CH 3 )2)
13C NMR (100 MHz, CDCl3): δ = 159.0 (C=O), 153.2 (C=O), 149.9 (C=O), 143.9 (C6), 128.7, 128.6 (CH=CH), 122.5, 122.4 (CH=CH), 96.5 (C 5), 84.3, 84.2 (O-CH2-O), 73.5 (CH(CH3)2), 45.1 (2C, U-CH2), 27.0, 25.6 (P-CH2), 21.6 (2C, CH(CH3)2)
31P NMR (162 MHz, CDCl3): δ = 26.6
N1-クロチル-5-置換ウラシル (1 当量)および実施例 11により製造されたHDP-POC-アリルホスホネート (1.3 当量)のCH2Cl2 (25 mL/mmol)溶液に、IPr 触媒 (0.05 当量)を加えた。この溶液を、乾燥アルゴン陽圧下、示された時間、室温で撹拌した。全ての揮発性物質を蒸発後、残渣をシリカゲルのクロマトグラフィー(EtOAc/EP)で精製した。
実施例 28.1 で製造したN1-[(E)- O-ヘキサデシルオキシプロピル イソプロピルオキシカルボニルオキシメチル-ホスフィニル-2-ブテニル]-5-置換ウラシルに、脱塩水中の水酸化ナトリウムの0,1M 溶液 (1ml)を加えた。この溶液を室温で4時間撹拌する。該塩基性溶液を酸性DOWEX 樹脂 50w8 で中和し、DCM (1 ml)で2回洗浄する。全ての揮発性物質を蒸発後、純粋な生成物が直接得られる。
実施例29〜38の化合物は、上記の一般的な手順にしたがって合成される。
31P NMR (162 MHz, CDCl3): δ = 26.7
13C NMR (100 MHz, CDCl3): δ = 159.1 (C=O), 153.2 (C=O), 149.8 (C=O), 140.3 (C6), 128.6, 128.5 (CH=CH), 125.6, 125.5 (CH=CH), 109.0 (C 5), 84.5, 84.4 (O-CH2-O), 73.2 (CH(CH3)2), 71.2 (O-CH2-CH2-(CH2)13-CH3), 66.4 (P-O-CH2-CH2-CH2-O), 63.7, 63.6 (P-O-CH2-CH2-CH2-O), 49.5, 49.4 (U-CH2), 31.9, 31.1, 30.7, 30.6, 29.7 (2C), 29.6 (2C), 29.5, 29.3, 26.1, 22.6, 21.6 (2C) (CH 2 -P, CH(CH3)2, P-O-CH2-CH2-CH2-O, O-CH2-CH2-(CH2) 13 -CH3), 14.1 (O-CH2-CH2-(CH2)13-CH3)
31P NMR (162 MHz, CDCl3): δ = 26.6
31P NMR (162 MHz, CDCl3): δ = 26.5
31P NMR (162 MHz, CDCl3): δ = 26.6
31P NMR (162 MHz, CDCl3): δ = 26.5
31P NMR (162 MHz, CDCl3) δ = 25.9
31P NMR (162 MHz, CD3OD): δ = 25.4
31P NMR (162 MHz, CD3OD): δ = 25.7
31P NMR (162 MHz, CD3OD): δ = 25.4
アルゴン下、10℃で、実施例 13により製造されたビス-(POM) 1-ヒドロキシメチル-アリルホスホネート (1 当量)、複素環塩基 (1.5 当量)、トリフェニルホスフィン (1.5 当量)のジオキサン (5 mL/mmol)溶液に、ジイソプロピルアゾジカルボキシレート (1.5 当量)を加えた。この溶液を室温で20時間撹拌した。全ての揮発性物質の蒸発後、残渣をシリカゲルのクロマトグラフィー (MeOH/DCM)で精製した。
実施例40〜42の化合物は、上記の一般的手順にしたがって合成される。
13C NMR (100 MHz, CDCl3): δ = 176.8 (C=O), 155.4 (C6), 153.1 (C2), 149.9 (C4), 140.1 (C8), 130.0, 129.8 (CH=CH), 123.4, 123.2 (CH=CH), 119.6 (C5), 81.6 (2C, O-CH2-O), 44.9 (2C, B-CH2), 38.7 (C(CH3)3), 31.5, 30.1 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.50
13C NMR (100 MHz, CDCl3): δ = 176.8 (C=O), 152.0 (C2), 151.6, 151.1 (C4およびC6), 144.7 (C8), 131.6 (C5), 128.9, 128.7 (CH=CH), 124.6, 124.5 (CH=CH), 81.6, 81.5 (O-CH2-O), 45.5, 45.4 (B-CH2), 38.7 (C(CH3)3), 31.4, 30.0 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.05
13C NMR (162 MHz, CDCl3): δ = 176.8 (C=O), 159.1 (C6), 153.6 (C4), 151.3 (C2), 141.8 (C8), 129.4, 129.3 (CH=CH), 125.1 (C5), 123.6, 123.5 (CH=CH), 81.6, 81.5 (O-CH2-O), 44.9 (B-CH2), 38.7 (C(CH3)3), 31.4, 30.0 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.35.
シクロプロピルアミンとジクロロメタンの1:9 混合物 (20 mL/mmol)中の6-クロロプリンの溶液を、40℃で20時間撹拌する。全ての揮発性物質の蒸発後、残渣をシリカゲルのクロマトグラフィー (MeOH/DCM)で精製した。
実施例44および45の化合物は、この手順にしたがって合成される。
31P NMR (162 MHz, CDCl3): δ = 26.57
31P NMR (162 MHz, CDCl3): δ = 26.77
脱塩水とギ酸の1:1 混合物 (20 mL/mmol)中の6-クロロプリンの溶液を、40℃で20時間撹拌する。全ての揮発性物質の蒸発後、残渣をシリカゲルのクロマトグラフィー (MeOH/DCM)で精製した。
実施例47および48の化合物は、この手順にしたがって合成される。
13C NMR (100 MHz, CDCl3): δ = 176.8 (C=O), 159.1 (C6), 148.9 (C4), 145.0 (C2), 139.7 (C8), 129.7, 129.5 (CH=CH), 124.5 (C5), 123.8, 123.7(CH=CH), 81.6 (2C, O-CH2-O), 45.3 (2C, B-CH2), 38.7 (C(CH3)3), 31.4, 30.0 (CH2-P), 26.8 (C(CH3)3)
31P NMR (162 MHz, CDCl3): δ = 26.40
13C NMR (100 MHz, CDCl3): δ = 176.9 (C=O), 159.0 (C6), 153.9 (C2), 151.4 (C4), 137.2 (C8), 130.6, 130.4 (CH=CH), 122.7, 122.6 (CH=CH), 116.8 (C5), 81.7, 81.6 (O-CH2-O), 44.8 (B-CH2), 38.7 (C(CH3)3), 31.4, 30.0 (CH2-P), 26.8 (C(CH3)3)
31P NMR (100 MHz, CDCl3): δ = 27.04
Log D (pH= 7.4)は、 ChemAxonからのMarvinSketch 5.3 (Method Weighter)を用いて計算された。
結果は、Log D、すなわち、 pH=7.4での水/オクタノール分配率の対数を提示する図1で示される。
Log Dが大きいほど、化合物はより親油性であり、それゆえ、その生物学的利用能はよりよいであろう。
請求項の式でR=R'=POM; R=R'=POC; R=POCおよびR'=HDP、ならびにR=H およびR'=HDPである本発明の化合物(実施例 16〜48)全て、対応するリン酸(R=R'=H)よりはるかに大きいLog Dを有する。
Claims (12)
- 式(I)
Rは、
* 式(1)
p は、
* R = R2 で、R2 は水素、ハロゲン、OH、N3、NH2、エポキシ基および類似物、脱離基(スルホネート、ハロゲン、...)、Pd(0)で触媒される金属交換反応工程に関与する脱離基ならびにカルボニル基を含む群から選択され、
n は0〜5の整数であり、
X およびY は互いに独立して、水素、ハロゲン、直鎖もしくは分枝の(C1-C6)アルキル基またはヒドロキシメチル基を表し、
R'およびR"は互いに独立して、
* -式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1C6)アルコキシ基である)
のオキシメチルカルボニル基、但し、Rがシス-プロペニル
-式(3)
R3 は直鎖もしくは分枝の(C1-C6)アルキル基である)
のチオエチルカルボニル基、
-限定されないが、ヘキサデシルオキシプロピル(HDP)-、オクタデシルオキシエチル-、オレイルオキシプロピル-およびオレイルオキシエチル-エステル)を含む群の中で選択される親油性鎖、但し、n=0のとき、R はシス-プロペニル
を含む基から選択される基を表すか、または
* R'およびR"はそれらが結合するホスフェート原子と一緒に、式(4)
のシクロアルキレン基を形成する]
の化合物である、但し、
-
が、基
である請求項1に記載の化合物に相当する、式
- R が請求項1で定義されたとおりの R2 に等しい請求項1に記載の化合物に相当する、式
-
-
- 薬物Dを、
Rが、
* 式(1)
p は、
* R = R2 で、R2 は水素、ハロゲン、OH、N3、NH2、エポキシ基および類似物、脱離基(スルホネート、ハロゲン、...)、Pd(0)で触媒される金属交換反応工程に関与する脱離基ならびにカルボニル基を含む群から選択され、
n が0〜5の整数であり、
X およびY が互いに独立して、水素、ハロゲン、直鎖もしくは分枝の(C1-C6)アルキル基またはヒドロキシメチル基であり、
R'およびR"が互いに独立して、
* -式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1C6)アルコキシ基である)
R3 は直鎖もしくは分枝の(C1-C6)アルキル基である)
のオキシメチルカルボニル基、
-限定されないが、ヘキサデシルオキシプロピル(HDP)-、オクタデシルオキシエチル-、オレイルオキシプロピル-およびオレイルオキシエチル-エステル)を含む群から選択される親油性鎖
を含む基から選択される基を表すか、
* R'およびR"が、それらが結合するホスフェート原子と一緒に、式(4)
のシクロアルキレン基を形成する、
である式(I)の化合物と接触させる工程を含む親油性プロ-ドラッグを製造する方法。 - 前記方法が、請求項2、4および5のいずれか一つに記載の少なくとも一つの化合物を、オレフィン基を有する薬物Dと接触させる工程を含むオレフィン-メタセシス反応である請求項6に記載の方法。
- 前記方法が、請求項2、4および5のいずれか一つに記載の少なくとも一つの化合物を、ハロゲン、TfO、スルホン...のような脱離基を有する薬物Dと接触させる工程を含む請求項6に記載の方法。
- a) 式(5)
の化合物を提供し、
b) 式(5)の化合物を式(I-1)
の化合物と反応させ、式(II-1)の化合物を得、
c) 式(II-1)の化合物を単離する
工程を含む、式(II-1)
D はオレフィン基を有する薬物であり、
A は1以上の2重結合を含む(C1-C6)アルケニル基であり、
R'およびR"は互いに独立して、
* -式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1-C6)アルコキシ基である)
のオキシメチルカルボニル基、
-式(3)
のチオエチルカルボニル基、
-親油性鎖
を表すか、または
* R'およびR" は、それらが結合するホスフェート原子と一緒に、式(4)
のシクロアルキレン基を形成する]
の化合物を製造するための請求項7に記載の方法。 - a) 式(6)
b) 求核置換反応で、式(6)の化合物を式(I-2)
の化合物と反応させ、式(II-2)の化合物を得、
c) 式(II-2)の化合物を単離する
の工程を含む、式(II-2)
m = 0 または1であり、
D は薬物であり、
R'およびR"は互いに独立して、
* - 式(2)
R1 およびR'1 は互いに独立して、水素または(C1-C4)アルキル基であり、
R'2 は、直鎖もしくは分枝の(C1-C6)アルキル基または直鎖もしくは分枝の(C1-C6)アルコキシ基である)
のオキシメチルカルボニル基、
- 式(3)
のチオエチルカルボニル基、
- 親油性鎖
を含む基から選択される基を表すか、または
* R'およびR"は、それらが結合するホスホネート原子と一緒に、式(4)
のシクロアルキレン基を形成する]
の化合物を製造するための請求項6に記載の方法。 - プロ-ドラッグとして役に立つホスホネート誘導体の合成における中間体として、式
- 薬物としての式
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305562.2 | 2009-06-18 | ||
EP09305562A EP2270021A1 (en) | 2009-06-18 | 2009-06-18 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability |
PCT/EP2010/058567 WO2010146127A1 (en) | 2009-06-18 | 2010-06-17 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012530113A true JP2012530113A (ja) | 2012-11-29 |
JP2012530113A5 JP2012530113A5 (ja) | 2013-08-01 |
Family
ID=41171101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012515500A Pending JP2012530113A (ja) | 2009-06-18 | 2010-06-17 | より良好な生物学的利用能を示すホスホネート誘導体の合成のためのホスホネートシントン |
Country Status (6)
Country | Link |
---|---|
US (1) | US8785629B2 (ja) |
EP (2) | EP2270021A1 (ja) |
JP (1) | JP2012530113A (ja) |
CA (1) | CA2764827C (ja) |
ES (1) | ES2601849T3 (ja) |
WO (1) | WO2010146127A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021177339A1 (ja) * | 2020-03-04 | 2021-09-10 | 富士フイルム和光純薬株式会社 | ホスホン酸エステルの製造方法、リン酸エステルの製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012034719A1 (en) * | 2010-09-14 | 2012-03-22 | Centre National De La Recherche Scientifique | Novel antiviral acyclic nucleoside phosphonates |
EP4370136A2 (en) * | 2021-07-15 | 2024-05-22 | Alnylam Pharmaceuticals, Inc. | Simple chemical approaches to introduce 2,6-diaminopurine and 2-aminoadenine conjugates into oligonucleotides |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05507938A (ja) * | 1990-06-13 | 1993-11-11 | グラツィエル,アーノルド | 含リンプロドラッグ |
JPH07506121A (ja) * | 1993-02-19 | 1995-07-06 | シンファ・ソシエテ・アノニム | 置換ホスホネート,その製法およびその化合物含有の医薬組成物 |
WO1996040704A1 (en) * | 1995-06-07 | 1996-12-19 | Sardinian Antiviral Research Consortium Sarc S.C.R.L. | Pyrazole-related derivatives endowed with antitumor and antiviral activities, procedures for their preparation, pharmaceutical formulations containing them |
US5635449A (en) * | 1995-04-07 | 1997-06-03 | American Cyanamid Company | Arylthioalkyl- and arylthioalkenylphosphonic acids and derivatives thereof useful as herbicidal agents |
JP2000502355A (ja) * | 1996-01-16 | 2000-02-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | ミクロソーム・トリグリセリド転移プロテインの立体配座制限芳香族抑制剤および方法 |
WO2001039724A2 (en) * | 1999-12-03 | 2001-06-07 | The Regents Of The University Of California, San Diego | Phosphonate compounds |
WO2004035577A2 (en) * | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
WO2006020417A2 (en) * | 2004-08-04 | 2006-02-23 | Virginia Tech Intellectual Properties, Inc. | Alkene mimics |
JP2007238624A (ja) * | 2003-04-25 | 2007-09-20 | Gilead Sciences Inc | 抗癌ホスホネートアナログ |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6814978A (ja) | 1967-10-30 | 1969-05-02 | ||
BR6914868D0 (pt) * | 1969-01-23 | 1973-03-20 | & Co Inc Merck | Processos quimicos |
JPS6069089A (ja) | 1983-09-26 | 1985-04-19 | Nissan Chem Ind Ltd | ジヒドロピリジン−5−ホスホネ−ト誘導体およびその製造法 |
EP0521622B1 (en) | 1991-07-03 | 1997-08-13 | PHARMACIA & UPJOHN COMPANY | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories |
DE4343599A1 (de) | 1993-12-21 | 1995-06-22 | Bayer Ag | Verwendung von Phosphonsäureestern zur Behandlung von Hirnleistungsstörungen und Depressionen |
IT1290444B1 (it) | 1997-03-27 | 1998-12-03 | Boehringer Mannheim Italia | Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale |
TWI332956B (en) | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
EP1551418A4 (en) | 2002-09-19 | 2006-05-03 | Ilex Oncology Res Sarl | SUBSTITUTED KETOPHOSPHONATE COMPOUNDS WITH BONE ANABOLIC EFFECT |
EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
WO2008096002A1 (en) | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
-
2009
- 2009-06-18 EP EP09305562A patent/EP2270021A1/en not_active Withdrawn
-
2010
- 2010-06-17 JP JP2012515500A patent/JP2012530113A/ja active Pending
- 2010-06-17 EP EP10725716.4A patent/EP2443130B1/en not_active Not-in-force
- 2010-06-17 WO PCT/EP2010/058567 patent/WO2010146127A1/en active Application Filing
- 2010-06-17 CA CA2764827A patent/CA2764827C/en not_active Expired - Fee Related
- 2010-06-17 ES ES10725716.4T patent/ES2601849T3/es active Active
- 2010-06-17 US US13/377,652 patent/US8785629B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05507938A (ja) * | 1990-06-13 | 1993-11-11 | グラツィエル,アーノルド | 含リンプロドラッグ |
JPH07506121A (ja) * | 1993-02-19 | 1995-07-06 | シンファ・ソシエテ・アノニム | 置換ホスホネート,その製法およびその化合物含有の医薬組成物 |
US5635449A (en) * | 1995-04-07 | 1997-06-03 | American Cyanamid Company | Arylthioalkyl- and arylthioalkenylphosphonic acids and derivatives thereof useful as herbicidal agents |
WO1996040704A1 (en) * | 1995-06-07 | 1996-12-19 | Sardinian Antiviral Research Consortium Sarc S.C.R.L. | Pyrazole-related derivatives endowed with antitumor and antiviral activities, procedures for their preparation, pharmaceutical formulations containing them |
JP2000502355A (ja) * | 1996-01-16 | 2000-02-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | ミクロソーム・トリグリセリド転移プロテインの立体配座制限芳香族抑制剤および方法 |
WO2001039724A2 (en) * | 1999-12-03 | 2001-06-07 | The Regents Of The University Of California, San Diego | Phosphonate compounds |
WO2004035577A2 (en) * | 2002-10-16 | 2004-04-29 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
JP2007238624A (ja) * | 2003-04-25 | 2007-09-20 | Gilead Sciences Inc | 抗癌ホスホネートアナログ |
WO2006020417A2 (en) * | 2004-08-04 | 2006-02-23 | Virginia Tech Intellectual Properties, Inc. | Alkene mimics |
Non-Patent Citations (6)
Title |
---|
JPN6014036732; Ettari, Roberta; Nizi, Emanuela; Di Francesco, Maria Emilia; et al.: 'Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors' ChemMedChem 3(7), 2008, 1030-1033 * |
JPN6014036734; Kumamoto, Hiroki; Topalis, Dimitri; Broggi, Julie; Pradere, Ugo; Roy,Vincent; Berteina-Raboin, Sabin: 'Preparation of acyclo nucleoside phosphonate analogues based on cross-metathesis' Tetrahedron 64(16), 2008, 3517-3526 * |
JPN6014036735; Chavez, Medardo R.; Zhao, Piyu; Kovacs, Zoltan; Sherry, A. Dean: 'A synthetic route to cell permeable, macrocyclic-based phosphonate acyloxymethyl esters' Letters in Organic Chemistry 1(2), 2004, 194-200 * |
JPN6014036738; Gopalakrishnan, B.; Aparna, V.; Jeevan, J.; Ravi, M.; Desiraju, G. R.: 'A Virtual Screening Approach for Thymidine Monophosphate Kinase Inhibitors as Antitubercular Agents' Journal of Chemical Information and Modeling 45(4), 2005, 1101-1108 * |
JPN6014036740; Kabbaj, Youssef; Lazrek, Hassan Bihi; Barascut, Jean Louis; Imbach, Jean Louis: 'Synthesis and biological activity of some unsaturated 6-aza-uracil acyclo-nucleosides' Nucleosides, Nucleotides & Nucleic Acids 24(3), 2005, 161-172 * |
JPN6014036742; Revankar, G. R.; Ojwang, J. O.; Mustain, S. D.; Rando, R. F.; et al: 'Thiazolo[4,5-d]pyrimidines. Part II. Synthesis and anti-human cytomegalovirus activity in vitro of c' Antiviral Chemistry & Chemotherapy 9(1), 1998, 53-63 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021177339A1 (ja) * | 2020-03-04 | 2021-09-10 | 富士フイルム和光純薬株式会社 | ホスホン酸エステルの製造方法、リン酸エステルの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2443130A1 (en) | 2012-04-25 |
EP2270021A1 (en) | 2011-01-05 |
CA2764827A1 (en) | 2010-12-23 |
US20120142897A1 (en) | 2012-06-07 |
WO2010146127A1 (en) | 2010-12-23 |
US8785629B2 (en) | 2014-07-22 |
EP2443130B1 (en) | 2016-08-03 |
CA2764827C (en) | 2018-08-21 |
ES2601849T3 (es) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pradere et al. | Synthesis of nucleoside phosphate and phosphonate prodrugs | |
Starrett et al. | Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy) ethyl] adenine (PMEA) | |
KR101178319B1 (ko) | 포스폰산 유도체 및 p2y12 수용체 길항물질로서 이들의 용도 | |
AU2014268040B2 (en) | Phosphoric acid/phosphonic acid derivatives and medicinal uses thereof | |
JPH09506334A (ja) | ヌクレオチドアナログ | |
CA2890676A1 (en) | Phosphonucleosides useful in the treatment of viral disorders | |
EP1753762A1 (en) | Lewis acid mediated synthesis of cyclic esters | |
EP1866319A1 (en) | Phosphono-pent-2-en-1-yl nucleosides and analogs | |
CN106188192A (zh) | 含d-氨基酸酯的核苷氨基磷酸膦酸酯衍生物及其医药用途 | |
WO1999051613A1 (en) | Prodrugs of phosphorous-containing pharmaceuticals | |
Bessières et al. | Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates | |
SK281788B6 (sk) | Deriváty kyseliny bisfosfónovej, spôsob ich prípravy a farmaceutický prostriedok s ich obsahom | |
EP2443130B1 (en) | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability | |
HUT72459A (en) | Unsaturated phosphonates derivatives of purines and pyrimidines | |
Ambrosi et al. | Synthesis of rovafovir etalafenamide (Part III): evolution of the synthetic process to the phosphonamidate fragment | |
Lavén et al. | Preparation of benzylphosphonates via a palladium (0)-catalyzed cross-coupling of H-phosphonate diesters with benzyl halides. Synthetic and mechanistic studies | |
Brel et al. | Synthesis and molecular structure of new acyclic analogues of nucleotides with a 1, 2-alkadienic skeleton | |
WO2003011221A2 (en) | PREPARATION AND USE OF α-KETO PHOSPHONATES | |
AU750407B2 (en) | Prodrugs of phosphorous-containing pharmaceuticals | |
AU2006298677A1 (en) | Phosphoantigen salts of organic bases and methods for their crystallization | |
KR20120124383A (ko) | 신규한 뉴클레오시드 포스포네이트 및 유사체 | |
Williams | Nucleoside Phosphonate Prodrugs: Synthesis and Antiviral Activity | |
Kuźnik et al. | A method for the synthesis of unsymmetric bisphosphoric analogs of α-amino acids | |
Lundy | New chemical methods for masking phosphates and phosphonates for drug delivery purposes | |
CZ20011145A3 (cs) | Antivirové purinové deriváty a jejich použití |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130617 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141203 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150929 |